Company profile

RIEMSER Arzneimittel AG is a company with tradition and a future.
Following its demerger from the Friedrich-Loeffler-Institute Riems Island (FLI), RIEMSER Arzneimittel AG has, within a period of just a few years, evolved to become one of East Germany’s largest producers and developers of pharmaceutical products.

RIEMSER Arzneimittel AG has affiliated branches in such German Federal States such as Saarland, Baden-Württemberg, and Saxony as well as abroad.

RIEMSER AG has more than 618 employees at various locations. In 2008, the group achieved sales of the order of 85,4 million euros.

RIEMSER Arzneimittel AG exports to more than 80 countries, including China, Russia and the U.S.A. Business transacted abroad will grow to more than 40 percent of total sales in fiscal 2009.

RIEMSER AG carries a well-diversified portfolio, which encompasses the areas human, veterinary, and dental. Its core competencies focus on oncology and dermatology as well as on dental products and anti-infectives, in veterinary, the emphasis is on animal vaccines.